abstract：:Bladder cancer is one of the leading causes of death in Europe and the United States. About 25% of patients with bladder cancer have advanced disease (muscle-invasive or metastatic disease) at presentation and are candidates for systemic chemotherapy. In the setting of metastatic disease, use of cisplatin-based regime...

journal_title：Cancer treatment reviews

authors： Morales-Barrera R,Suárez C,de Castro AM,Racca F,Valverde C,Maldonado X,Bastaros JM,Morote J,Carles J

更新日期：2016-11-01 00:00:00

abstract：:Borderline ovarian tumours (BOT) may occur in young women and have an excellent survival rate. Therefore, there is the obligation to put emphasis on fertility preservation in affected women. On the other hand, it has also been underlined that the disease should be managed with caution because these tumours can relapse...

journal_title：Cancer treatment reviews

authors： Mangili G,Somigliana E,Giorgione V,Martinelli F,Filippi F,Petrella MC,Candiani M,Peccatori F

更新日期：2016-09-01 00:00:00

abstract：:We review radiation therapy (RT) options available for prostate cancer, including external beam (EBRT; with conventional fractionation, hypofractionation, stereotactic body RT [SBRT]) and brachytherapy (BT), with an emphasis on the outcomes, toxicities, and contraindications for therapies. PICOS/PRISMA methods were us...

journal_title：Cancer treatment reviews

authors： Zaorsky NG,Shaikh T,Murphy CT,Hallman MA,Hayes SB,Sobczak ML,Horwitz EM

更新日期：2016-07-01 00:00:00

abstract：BACKGROUND:Data on the comparative efficacy of fulvestrant and other endocrine treatments are inconsistent. Clinical markers predictive of greater benefit from fulvestrant compared to the alternate endocrine agents have not been identified. METHODS:We searched the literature from inception to May 2015, using MEDLINE, ...

journal_title：Cancer treatment reviews

authors： Graham J,Pitz M,Gordon V,Grenier D,Amir E,Niraula S

更新日期：2016-04-01 00:00:00

abstract：BACKGROUND:The incidence of brain metastases (BM) in melanoma patients is common and associated with poor prognosis. MAP-kinase inhibitors and immunologic checkpoint blockade antibodies led to improved survival of metastatic melanoma patients; however, patients with BM are under-represented or excluded from the majorit...

journal_title：Cancer treatment reviews

authors： Spagnolo F,Picasso V,Lambertini M,Ottaviano V,Dozin B,Queirolo P

更新日期：2016-04-01 00:00:00

abstract：:The androgen receptor (AR) plays a key role in progression to metastatic castration-resistant prostate cancer (mCRPC). Despite the recent progress in targeting persistent AR activity with the next-generation hormonal therapies (abiraterone acetate and enzalutamide), resistance to these agents limits therapeutic effica...

journal_title：Cancer treatment reviews

authors： Ciccarese C,Santoni M,Brunelli M,Buti S,Modena A,Nabissi M,Artibani W,Martignoni G,Montironi R,Tortora G,Massari F

更新日期：2016-02-01 00:00:00

abstract：:Cyclophosphamide is considered one of the most successful chemotherapy drugs and is listed on the World Health Organisations List of Essential Medicines. Since its initial synthesis in 1958, it has been widely used to treat a range of cancers but its use has been declining due to the advent of platinum based and other...

journal_title：Cancer treatment reviews

authors： Madondo MT,Quinn M,Plebanski M

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:Surgery is the only curative treatment for primary cutaneous melanoma, therefore it is important to determine excision margins that minimise risk of local recurrence, distant recurrence and death. METHODS:MEDLINE, EMBASE and Cochrane CENTRAL were searched from 2009 to 2015. Inclusion criteria were: populati...

journal_title：Cancer treatment reviews

authors： Wheatley K,Wilson JS,Gaunt P,Marsden JR

更新日期：2016-01-01 00:00:00

abstract：:Immunotherapy represents a major breakthrough in cancer therapy in recent years. Immune-checkpoint blockade using PD-1 and PD-L1 antibodies appears to be one of the most promising immunotherapy approaches. Immunotherapy differs from conventional cancer treatment because of its ability to produce durable responses in s...

journal_title：Cancer treatment reviews

authors： Lote H,Cafferkey C,Chau I

更新日期：2015-12-01 00:00:00

abstract：:Checkpoint blockades turn on a new paradigm shift in immunotherapy for cancer. Remarkable clinical efficacy, durable response and low toxicity of programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockades have been observed in various malignancies. However, a lot of cancer patients failed to resp...

journal_title：Cancer treatment reviews

authors： Meng X,Huang Z,Teng F,Xing L,Yu J

更新日期：2015-12-01 00:00:00

abstract：BACKGROUND:The immune system plays an important role in cancer pathogenesis. A low lymphocyte-to-monocyte ratio (LMR), as a simple biomarker of host immune system, has been suggested to be related to poor prognosis in various cancers. We performed a systematic review and meta-analysis to quantify the prognostic value o...

journal_title：Cancer treatment reviews

authors： Nishijima TF,Muss HB,Shachar SS,Tamura K,Takamatsu Y

更新日期：2015-12-01 00:00:00

abstract：:Differentiated thyroid cancer is the most common endocrine malignancy, and its incidence has been rising rapidly over the past 10 years. Although most patients with this disease have an excellent prognosis, a subset develops a more aggressive disease phenotype refractory to conventional therapies. Until recently, ther...

journal_title：Cancer treatment reviews

authors： Carneiro RM,Carneiro BA,Agulnik M,Kopp PA,Giles FJ

更新日期：2015-09-01 00:00:00

abstract：:RAS family proteins (including KRAS and NRAS) play important roles in the epidermal growth factor receptor (EGFR) signaling pathway. Mutations in RAS genes (occurring at loci in exons 2, 3, and 4) often result in constitutive activation of RAS proteins and persistent downstream signaling. Mutations in KRAS exon 2 (cod...

journal_title：Cancer treatment reviews

authors： Hecht JR,Douillard JY,Schwartzberg L,Grothey A,Kopetz S,Rong A,Oliner KS,Sidhu R

更新日期：2015-09-01 00:00:00

abstract：:Due to differences in anatomy, primary rectal and colon cancer require different staging procedures, different neo-adjuvant treatment and different surgical approaches. For example, neoadjuvant radiotherapy or chemoradiotherapy is administered solely for rectal cancer. Neoadjuvant therapy and total mesorectal excision...

journal_title：Cancer treatment reviews

authors： Tamas K,Walenkamp AM,de Vries EG,van Vugt MA,Beets-Tan RG,van Etten B,de Groot DJ,Hospers GA

更新日期：2015-09-01 00:00:00

abstract：:Recently, non-small cell lung cancer (NSCLC) has been partly subclassified into molecularly-defined oncogene "addicted" tumors for which targeted agents are available. Tyrosine kinase inhibitors (TKI) are currently approved for patients with an activating epidermal growth factor receptor (EGFR) mutation or anaplastic ...

journal_title：Cancer treatment reviews

authors： Hendriks LE,Schoenmaekers J,Zindler JD,Eekers DB,Hoeben A,De Ruysscher DK,Dingemans AM

更新日期：2015-07-01 00:00:00

abstract：:Diffusion-weighted magnetic resonance imaging (DW-MRI) is used extensively to improve tumour detection and localization because it offers excellent soft tissue contrast between malignant and non-malignant tissues. It also provides a quantitative biomarker; the apparent diffusion coefficient (ADC) can be derived from D...

journal_title：Cancer treatment reviews

authors： Bollineni VR,Kramer G,Liu Y,Melidis C,deSouza NM

更新日期：2015-06-01 00:00:00

abstract：:Tumour budding reflects a detachment of tumour cells at the invasive front of carcinomas and is presumed to be an early step in the metastatic process. Tumour budding has received some attention in colorectal cancer as it has been proposed as an additional prognostic factor in colorectal cancer that may stratify patie...

journal_title：Cancer treatment reviews

authors： van Wyk HC,Park J,Roxburgh C,Horgan P,Foulis A,McMillan DC

更新日期：2015-02-01 00:00:00

abstract：:Low Grade Serous Ovarian Carcinoma, LGSOC, is certainly a rare disease, accounting for only a small proportion of all ovarian carcinomas, nevertheless in the last decade we have acquired many data about its molecular and clinical features and it has been largely accepted that it has distinct pathogenesis, genetic aber...

journal_title：Cancer treatment reviews

authors： Della Pepa C,Tonini G,Santini D,Losito S,Pisano C,Di Napoli M,Cecere SC,Gargiulo P,Pignata S

更新日期：2015-02-01 00:00:00

abstract：:Approximately 5-10% of breast cancer cases might be inheritable, up to 30% of which are due to BRCA1/2 mutations. During the past few years and thanks to technology evolution, we have been witnesses of an intensive search of additional genes with similar characteristics, under the premise that successful gene discover...

journal_title：Cancer treatment reviews

authors： Economopoulou P,Dimitriadis G,Psyrri A

更新日期：2015-01-01 00:00:00

abstract：:TP53 (p53) is the most frequently mutated gene in cancer, being altered in approximately 50% of human malignancies. In most, if not all, cancers lacking mutation, wild-type (WT) p53 is inactivated by interaction with cellular (MDM2/MDM4) or viral proteins, leading to its degradation. Because of its near universal alte...

journal_title：Cancer treatment reviews

authors： Duffy MJ,Synnott NC,McGowan PM,Crown J,O'Connor D,Gallagher WM

更新日期：2014-12-01 00:00:00

abstract：:Historically, the median overall survival for patients with stage IV melanoma was less than 1 year and the 5-year survival rate was ∼10%. Recent advances in therapy have raised 5-year survival expectations to ∼20%. Notably, a subset of melanoma patients who receive immunotherapy with high-dose interleukin-2, and now i...

journal_title：Cancer treatment reviews

authors： McDermott D,Lebbé C,Hodi FS,Maio M,Weber JS,Wolchok JD,Thompson JA,Balch CM

更新日期：2014-10-01 00:00:00

abstract：:Cancer treatment is the most frequent cause of reduced fertility in cancer patients, with up to 80% of survivors affected. None of the established or experimental fertility preservation methods can assure parenthood, rather they may provide a future opportunity to overcome treatment induced sterility. Around 70-75% of...

journal_title：Cancer treatment reviews

authors： Linkeviciute A,Boniolo G,Chiavari L,Peccatori FA

更新日期：2014-09-01 00:00:00

abstract：:Neuroendocrine neoplasms are a low-incidence and heterogeneous group of malignancies. In the advanced stage, several therapeutic options can be discussed, including molecular-targeted agents, but biological predicting factors are lacking. A number of molecular targets have been studied over the last decade leading to ...

journal_title：Cancer treatment reviews

authors： Fazio N,Abdel-Rahman O,Spada F,Galdy S,De Dosso S,Capdevila J,Scarpa A

更新日期：2014-09-01 00:00:00

abstract：:Targeted therapies have unique toxicity profiles. Common adverse events include rash, diarrhea, hypertension, hypothyroidism, proteinuria, depigmentation, and hepatotoxicity. Some of these toxicities are caused by on-target, mechanism-associated effects, which can be stratified as to whether or not the targets are rel...

journal_title：Cancer treatment reviews

authors： Liu S,Kurzrock R

更新日期：2014-08-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) accounts for >80% of lung cancer cases and currently has an overall five-year survival rate of only 15%. Patients presenting with advanced stage NSCLC die within 18-months of diagnosis. Metastatic spread accounts for >70% of these deaths. Thus elucidation of the mechanistic basis of ...

journal_title：Cancer treatment reviews

authors： Wood SL,Pernemalm M,Crosbie PA,Whetton AD

更新日期：2014-05-01 00:00:00

abstract：:In colon cancer, the biological significance of lymphatic tumour spread remains a matter of debate, which impacts on related questions such as the ideal extent of lymphadenectomy and the prognostic significance of lymph node counts. Several lines of evidence suggest that metastasis to locoregional nodes occurs early a...

journal_title：Cancer treatment reviews

authors： Willaert W,Mareel M,Van De Putte D,Van Nieuwenhove Y,Pattyn P,Ceelen W

更新日期：2014-04-01 00:00:00

abstract：:Antiangiogenic agents (AAs) have reported grater efficacy compared to interferon. Despite these advances, radiological complete response to therapy is rare. We meta-analyzed the incidence of complete response in patients treated with AAs and in controls in main randomized clinical trials for first-line therapy in meta...

journal_title：Cancer treatment reviews

authors： Iacovelli R,Alesini D,Palazzo A,Trenta P,Santoni M,De Marchis L,Cascinu S,Naso G,Cortesi E

更新日期：2014-03-01 00:00:00

abstract：:Galectins belong to a family of carbohydrate-binding proteins with an affinity for β-galactosides. Galectin-1 is differentially expressed by various normal and pathologic tissues and displays a wide range of biological activities. In oncology, galectin-1 plays a pivotal role in tumor growth and in the multistep proces...

journal_title：Cancer treatment reviews

authors： Astorgues-Xerri L,Riveiro ME,Tijeras-Raballand A,Serova M,Neuzillet C,Albert S,Raymond E,Faivre S

更新日期：2014-03-01 00:00:00

abstract：:This review summarizes emerging information regarding the Hedgehog (Hh) signaling pathway during neoplastic transformation in the gastrointestinal tract. Although there is a role for the well-established canonical pathway in which Hedgehog ligands interact with their receptor Patched, there is sufficient evidence that...

journal_title：Cancer treatment reviews

authors： Merchant JL,Saqui-Salces M

更新日期：2014-02-01 00:00:00

abstract：:Standard first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) is docetaxel plus prednisone; however, patients will usually experience disease progression during or after docetaxel treatment due to inherent or acquired resistance. Before 2010, second-line options for mCRPC were limited. Howe...

journal_title：Cancer treatment reviews

authors： Bahl A,Masson S,Birtle A,Chowdhury S,de Bono J

更新日期：2014-02-01 00:00:00

abstract：:The N-methyl-N'-nitroso-guanidine human osteosarcoma transforming gene (MET) receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) control cellular signaling cascades that direct cell growth, proliferation, survival, and motility. Aberrant MET/HGF activation has been observed in many tumor types, can ...

journal_title：Cancer treatment reviews

authors： Scagliotti GV,Novello S,von Pawel J

更新日期：2013-11-01 00:00:00

abstract：:The availability of sensitive methods has allowed the detailed study of circulating tumor cells only recently. Evolving evidence support the prognostic and predictive role of these cells in patients affected by several solid tumors, including colorectal cancer. Ongoing studies are aimed at confirming that the molecula...

journal_title：Cancer treatment reviews

authors： Torino F,Bonmassar E,Bonmassar L,De Vecchis L,Barnabei A,Zuppi C,Capoluongo E,Aquino A

更新日期：2013-11-01 00:00:00

abstract：BACKGROUND AND AIMS:The use of oral anticancer drugs has increased in modern oncology treatment. The move from intravenous treatments towards oral anticancer drugs has increased the patients' own responsibility to take oral anticancer drugs as being prescribed. High rates of non-adherence to oral anticancer drugs have ...

journal_title：Cancer treatment reviews

authors： Verbrugghe M,Verhaeghe S,Lauwaert K,Beeckman D,Van Hecke A

更新日期：2013-10-01 00:00:00

abstract：:Prostate cancer is androgen-dependent in its early stages and androgen deprivation therapy represents the most effective first-line therapeutic approach. However, after an initial remission, prostate cancer progresses towards the castration resistant prostate cancer (CRPC) stage, with increased malignancy and resistan...

journal_title：Cancer treatment reviews

authors： Limonta P,Manea M

更新日期：2013-10-01 00:00:00

abstract：:Despite the available prevention and early detection strategies, advanced squamous-cell carcinoma of the uterine cervix remains a major concern for public health. Systemic treatment with cisplatin, either in combination with external beam irradiation for locally advanced disease, or as monotherapy for recurrent/metast...

journal_title：Cancer treatment reviews

authors： Mountzios G,Soultati A,Pectasides D,Pectasides E,Dimopoulos MA,Papadimitriou CA

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:To provide an updated review of adverse events associated with sunitinib, pazopanib, bevacizumab, temsirolimus, axitinib, everolimus and sorafenib and their management. MATERIALS AND METHODS:We performed a PubMed and Cochrane-based review of side effects associated with the seven agents including product mo...

journal_title：Cancer treatment reviews

authors： Alasker A,Meskawi M,Sun M,Ismail S,Hanna N,Hansen J,Tian Z,Bianchi M,Perrotte P,Karakiewicz PI

更新日期：2013-06-01 00:00:00

abstract：:In the last few years, several drugs targeting signalling proteins critical for melanoma entered clinical evaluation. In 2011 vemurafenib (Zelboraf®, F. Hoffman-La Roche Ltd.) was approved for BRAF V600-positive melanoma and showed high overall response rates (48-53%). However recent results from a phase II clinical t...

journal_title：Cancer treatment reviews

authors： Nijenhuis CM,Haanen JB,Schellens JH,Beijnen JH

更新日期：2013-06-01 00:00:00

abstract：:The prognosis for patients with relapsed/progressive non-small cell lung cancer (NSCLC) remains poor. For first-line therapy, a number of platinum-based regimens are standard; second-line therapies include single-agent docetaxel, pemetrexed, and erlotinib. Treatment options for patients whose tumors have failed to res...

journal_title：Cancer treatment reviews

authors： Langer CJ,Mok T,Postmus PE

更新日期：2013-05-01 00:00:00

abstract：:An increasing number of women are diagnosed with cancer during pregnancy and lactation. Women are usually advised to interrupt breastfeeding during systemic anticancer treatment for fear of serious adverse effects to the nursed infant. However, the issue is poorly addressed in the literature and very few studies have ...

journal_title：Cancer treatment reviews

authors： Pistilli B,Bellettini G,Giovannetti E,Codacci-Pisanelli G,Azim HA Jr,Benedetti G,Sarno MA,Peccatori FA

更新日期：2013-05-01 00:00:00

abstract：:Nowadays, cancer has been a frequent disease, and the first or second most common cause of death worldwide. Despite a better understanding of the biology of cancer cells, the therapy of most cancers has not significantly changed for the past four decades. It is because conventional chemotherapies and/or radiation ther...

journal_title：Cancer treatment reviews

authors： Yi SY,Hao YB,Nan KJ,Fan TL

更新日期：2013-05-01 00:00:00